Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 11:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 9,819 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Single-arm Clear all
Terminated Phase 3 Interventional Results available

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

NCT02620384
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
Experimental: Placebo, Experimental: Metolazone
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 11, 2026, 11:26 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Not listed
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Results available

Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer

NCT02549989
View directory record Official record
Conditions
Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
LY3023414
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Sep 11, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Lung Squamous Cell Carcinoma, Pancreatic Cancer, Bile Duct Cancer, Endometrial Cancer, Melanoma Cancer, Urothelial Cancer
Interventions
PF-06940434, PF-06801591
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Recruiting Phase 2 Interventional

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

NCT05422690
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma
Interventions
Induction Chemotherapy Triplet Therapy, Concurrent Y-90 treatment, Consolidation Doublet Therapy:
Drug · Radiation
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 11, 2026, 11:26 AM EDT
Terminated Phase 1 Interventional Results available

Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)

NCT06056310
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT)
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Miami Beach, Florida • Detroit, Michigan • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FluSAFE: Flu SMS Alerts to Freeze Exposure

NCT03274310
View directory record Official record
Conditions
Influenza, Acute Respiratory Infection, Influenza-like Illness
Interventions
Educational text messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
Not listed
Enrollment
1,918 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Recruiting Not applicable Interventional

Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke

NCT07042152
View directory record Official record
Conditions
Chronic Stroke Patients
Interventions
Smartwatch App for Movement Variability, Smartwatch App for Active Time, Motivational Interviewing (Within Subjects)
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

NCT03106038
View directory record Official record
Conditions
Intraoperative Ureter Injury
Interventions
Nerindocianine for Injection
Drug
Lead sponsor
Li-Cor, Inc.
Industry
Eligibility
19 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 11, 2026, 11:26 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

NCT06496568
View directory record Official record
Conditions
PIK3CA-Mutated Cancers
Interventions
Inavolisib, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STI/HIV Intervention Behavioral Intervention Program

NCT04547413
View directory record Official record
Conditions
Sexually Transmitted Infections
Interventions
STI/HIV Intervention Behavioral Intervention Program
Behavioral
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 30 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Fayetteville, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Phase 1Phase 2 Interventional

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VB-111, Bevacizumab
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Topical Retinol on Epigenetic Changes and Expression of Certain Genes in the Skin Using Non-invasive Measurements

NCT06658847
View directory record Official record
Conditions
Retinoid, Skin Aging, Epigenomics
Interventions
Night Cream Usage, No Night Cream Usage
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 11, 2026, 11:26 AM EDT
Terminated Not applicable Interventional Results available

Trial to Evaluate UltraSound in the Treatment of Tibial Fractures

NCT00667849
View directory record Official record
Conditions
Tibial Fractures
Interventions
Exogen 4000+, Sham
Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Not applicable Interventional Results available

Caregivers' and Cancer Survivors' Psychological Distress & Symptom Management

NCT03743415
View directory record Official record
Conditions
Cancer
Interventions
Handbook, TIP-C plus Handbook
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
908 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 11, 2026, 11:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral and Neural Characteristics of Adaptive Speech Motor Control

NCT06164717
View directory record Official record
Conditions
Speech
Interventions
Auditory feedback perturbation during speech, Visual feedback perturbation during reaching, DBS stimulation ON/OFF
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
4 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Phase 3 Interventional Results available

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

NCT00225017
View directory record Official record
Conditions
HIV Infection, Hyperlipidemia
Interventions
Atazanavir, current antiretroviral regimen
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
5
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 11, 2026, 11:26 AM EDT
Withdrawn Phase 2 Interventional

Study of Panitumumab in the Treatment of Carcinoid Syndrome

NCT01172717
View directory record Official record
Conditions
Carcinoid Syndrome
Interventions
Panitumumab
Drug
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
2
States / cities
Boston, Massachusetts • Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 11, 2026, 11:26 AM EDT
Terminated Not applicable Interventional Results available

Study of Preoperative Boost Radiotherapy

NCT02482389
View directory record Official record
Conditions
Breast Cancer
Interventions
Single fraction of 7 Gy
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Not applicable Interventional

Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis

NCT02404974
View directory record Official record
Conditions
Osteoarthritis
Interventions
exercise
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 11, 2026, 11:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants

NCT04126213
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT 60 µg, RSV MAT 120 µg, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
534 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2021 · Synced Sep 11, 2026, 11:26 AM EDT
Terminated Phase 2 Interventional

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

NCT06322576
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
177Lu-PNT2002
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 11, 2026, 11:26 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Effect of a Fermented Dairy Protein With Prebiotic Fiber on GI Complaints

NCT06946017
View directory record Official record
Conditions
Digestive Health, Quality of Life
Interventions
Fermented dairy protein with prebiotic fiber supplement, Control placebo
Dietary Supplement
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 50 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 11, 2026, 11:26 AM EDT